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Almost a 20% of the residues of tau protein are phosphorylatable amino acids: serine, threonine, and tyrosine. In this paper
we comment on the consequences for tau of being a phosphoprotein. We will focus on serine/threonine phosphorylation. It
will be discussed that, depending on the modiﬁed residue in tau molecule, phosphorylation could be protective, in processes
like hibernation, or toxic like in development of those diseases known as tauopathies, which are characterized by an hyper-
phosphorylation and aggregation of tau.
1.Introduction
Tau protein was discovered as one of the brain microtubule-
associated proteins bound to in vitro assembled tubulin [1].
Tau protein appears as a series of diﬀerent polypeptides on
gel electrophoresis. These diﬀerent forms are generated by
alternative RNA splicing [2]o rb yd i ﬀerent phosphorylation
levels [3]. In every tau form, four diﬀerent regions could
be identiﬁed: the amino terminal region, the proline-rich
region, the microtubule binding region, and the carboxy
terminal region. Here, we will mainly comment on the
tau molecule of the largest tau form present in the central
nervous system (CNS) [4]. This molecule contains 441
residues. The N-terminal region (1–150 residues) and the
proline-rich region (151–239 residues) have been involved
in the interaction of tau protein with cell membranes
[5, 6]. The microtubule-binding region (residues 240–367)
contains four similar but not identical sequences involved
in the interaction with tubulin [7], the main component of
microtubules. The last part of the molecule is the C-terminal
region (residues 368 to 441). Curiously, for a speciﬁc residue,
threonine, there is a decreasing gradient in its presence from
the N-terminal to the C-terminal region in human tau.
Threonine is particularly abundant at the N-terminal region
[7]. Some of these threonines, residues 17, 30, 39, 50, 52, or
95, present in human tau are not always conserved in other
species and may have appeared during evolution in human
tau. None of these human tau threonines have been found to
bephosphorylated,butwecannotruleoutthatsomeofthese
sites could be modiﬁed with a very fast turnover.
2. Tau Functions
Tau is a neuronal microtubule-associated protein, and some
of its functions are related to that association that may
result in microtubule stabilization or the regulation of
axonal transport, but tau protein is a “sticky” protein that
could bind to other proteins, apart from tubulin (the main
component of microtubules), which could also facilitate
its subcellular localization at the cytoplasm close to the
membrane or in the nucleus. On the other hand, in the
neuron, tau is mainly present in axons, owing to a sorting
mechanism in which its level of phosphorylation may play
ar o l e[ 8], but tau can be also localized, at a low level, to
dendrites [9] whereit binds to PSD95 protein, a postsynaptic
component present in dendritic spines, which is bound to
glutamate (NMDA) receptors [10].
Some of tau functions could be regulated by phospho-
rylation. In many cases, tau phosphorylation can cause its
detachmentfrommicrotubules[11],andthosefunctionslike2 International Journal of Alzheimer’s Disease
microtubule stabilization and regulation of axonal transport
could be aﬀected by the change in the association of tau to
microtubules.
3. Phosphotau
Tau is a phosphoprotein that could be modiﬁed by diﬀerent
protein kinases at tyrosine, threonine, or serine residues. In
the longest CNS tau molecule, there are 80 serine/threonine
residues that are mainly present at the proline-rich and C-
terminal regions [11].
Tau kinases have been divided in proline- (PDPK) and
nonproline- (NPDPK) directed protein kinases, being GSK3
the PDPK that could modify more sites in tau molecule [12].
These sites are also mainly present at the proline-rich and C-
terminal regions.
GSK3 is a protein kinase originally identiﬁed due to its
role in glycogen metabolism regulation. GSK3β, one of its
isoforms, is abundant in the central nervous system and can
modify several neuronal proteins like tau [13].
Tau hyperphosphorylation takes place, at the CNS, in
several diseases (tauopathies), being the most predominant
of these disorders, Alzheimer disease. In the tauopathies,
tau protein is not only phosphorylated but also could be
found in aggregated form. In Alzheimer’s disease (AD) tau
protein can be assembled into the paired helical ﬁlaments
that form the aberrant structure known as neuroﬁbrillary
tangles [11]. Also, in AD, there is another aberrant structure
the senile plaques, composed by the beta-amyloid peptide.
A relationship between NFT and SP has been suggested
through GSK3 (see below and [14]).
4.GSK3 andAD
In Alzheimer’s disease postmortem brain material, tau
phosphorylation has been found to increase at several sites
modiﬁed by GSK3. In this way, the analysis of how an
increase in GSK3 activity could modify tau protein has been
deeply studied. It is known the involvement of factors like
wnt, insulin, or insulin-like growth factor in the regulation
of GSK3 [15]. It is also known that the accumulation of beta-
amyloid peptide facilitates tau phosphorylation by GSK3
through the interference with insulin or wnt pathways [16,
17]. Also, mutations in the protein presenilin-1 (PS-1) that
could result in the appearance of dementia with familiar
origin may aﬀect the interaction of PS-1 with the regulatory
subunit of PI3 kinase, decreasing the activity of this kinase
and the further activation of GSK3 [18]. On the other hand,
in nonfamilial dementia like sporadic Alzheimer disease,
the presence of apolipoprotein E4 isoform could facilitate
a higher GSK3 activity [19]. Also, a GSK3 polymorphism
has been associated with Alzheimer’s disease [20], and an
increase in GSK3 activity has been suggested to take place in
the brain of AD patients [21]. Finally, GSK3 phosphorylates
the majority of sites, on tau molecule, which are abnormally
phosphorylated in AD [12].
One of the consequences of tau phosphorylation by
GSK3 is a decrease of its interaction with microtubules
[22], which could result in a destabilization of microtubule
network [23]. Also, phosphorylation of tau by GSK3 (or
other kinases) may result in an increase or a decrease in its
interaction with other proteins. An increase was observed in
its interaction with prolyl isomerase 1 (PIN-1), a chaperone
protein that binds to phosphotau [24]. In this interaction
phosphothreonine 231 is involved. On the other hand,
Pin-1 could inhibit GSK3β, and a consequence of that is
a reduced phosphorylation of amyloid precursor protein
(APP), another important protein in AD. In the absence
of phosphorylation, the turnover of APP is increased [25].
Also, Pin-1 acts on T668P motif in APP to promote non-
amyloidogenic APP processing [26]. About GSK3 and APP
processing it should be indicated a report indicating that
GSK3, mainly GSK3α, can regulate APP processing and the
production of amyloid beta peptide [27].
Going back to tau phosphorylation, it has been observed
that the interaction of tau with cell membranes decreases
upon its phosphorylation [6]. In this binding, phosphoryla-
tion of serine 202 may play a role. Thus, the balance of kinase
and phosphatases acting on tau could be important for tau
functions and dysfunctions.
5. Is Phosphotau Toxic or
Protective in a Neuron?
Since tau phosphorylation may aﬀect tau functions, it was
suggested that phosphotau could be toxic. However, this
point has been widely discussed and is commented if phos-
phorylated tau is toxic, protective, or none of the above [28].
Working on Drosophila as a model it was indicated
that phosphotau is not toxic [29, 30]. Also, there are some
works suggesting that tau toxicity could be dependent in an
increase in its expression [31] or that the toxicity could be
related to its fragmentation, yielding some speciﬁc peptides
[32], or to its aggregation, but this point is also discussed,
since some works suggest a protective role for large tau
aggregates, although it may be insuﬃcient in damaged
neurons [33, 34]. More recently, it has been suggested a
toxicity for tau oligomers [35]. A possible relation between
tau phosphorylation and aggregation has been suggested.
In a mouse model for temporal dementia, chronic lithium
(a GSK3 inhibitor) treatment results in a decreased tau
phosphorylation and aggregation [36]. In another study a
similar result was found [37], being the site recognized
by antibody PHF-1 one of the phosphosites with a higher
decrease upon treatment with a GSK3 inhibitor. It may
suggest that tau phosphorylation at some sites may facilitate
tau aggregation. These results support the previous works
indicatingthatlargetauaggregatesexertnegligibleneurotox-
icity compared with soluble tau [38, 39].
A protective role for tau phosphorylation could be sug-
gested when that modiﬁcation could take place at threonine
181 [40] that could facilitate its binding to exosomes and
the release of tau excess [41]. Also phosphorylation at serine
202 could prevent the tau proteolysis by calpain [42], or
in some processes, like hibernation (see below), it could be
also protective [43]. Although poorly understood, there isInternational Journal of Alzheimer’s Disease 3
an endocrine regulation of hibernation, and a recent study
suggests that central system neurons are protected from low-
temperature cell death by certain endogenous substances
such as adenosine, opioids, and histamine [44].
On the other hand, tau toxicity resulting from tau phos-
phorylation could aﬀect to axonal transport, mitochondrial
respiration, or cytoskeletal changes [45, 46]. Also, the pres-
ence of hyperphosphorylated tau in dendritic spines impairs
synaptic activity [47], and tau phosphorylation by GSK3 in
the hippocampus results in a toxic gain of function [48, 49].
A way to study the role of tau phosphorylation on cell
toxicity is the use of pseudophosphorylated tau variants
where a serine or threonine residue is replaced by glutamatic
acid. Thus, it has been found that pseudophosphorylation
at the site recognized by antibody AT8, but not at the site
recognized by abPHF-1, prevents the interaction of tau with
neuronal membranes [50, 51].
Pseudophosphorylation of tau in ten diﬀerent sites of a
single molecule (including those sites recognized by AT8, ab
PHF-1, and phosphothreonine 231) results in a toxic action
and the induction of apoptosis [52].
Combined pseudophosphorylation at threonine 212,
threonine 231, and serine 262 causes neurodegeneration,
mainly through the presence of pseudophosphorylation at
threonine 212 [53]. A possible mechanism has been involved
for this toxicity: abnormal tau phosphorylation can result
in the sequestration of unmodiﬁed tau [54] or in that of
other microtubule associated proteins like MAP1 or MAP2
[23], promoting a net microtubule disassembly that could
aﬀect neuron cytoskeleton and promote neurodegeneration.
On the other hand, tau phosphorylated at Thr 231 is used
as a marker for neurodegeneration. It may suggest that tau
modiﬁed at that residue could be toxic [55].
All those results suggest that, depending on the modiﬁed
site, a protective or toxic function may take place and
that it could be due to diﬀerent conformational changes of
tau molecule. Although tau is an unstructured molecule,
it has been suggested that, in some conditions, it could
have a paperclip conformation. In this conformation, the C-
terminal end of tau interacts with the microtubule-binding
domain, whereas the N-terminal end could bind to the C-
terminal region, adopting a paperclip folding [56]. Pseu-
dophosphorylation at the AT8 site makes the N-terminal
region away from the C-terminal. On the other hand,
pseudophosphorylation at the PHF-1 site decreases the
interaction of C-terminal region with microtubule binding
domain [57]. Thus, phosphorylation at diﬀerent sites of
tau molecule could have diﬀerent consequences for tau
conformations and function. In this way, we will comment
moreonthephosphorylationoftauonthosesitesrecognized
by ab AT8 or ab PHF-1.
6. The Progression of Alzheimer and
the Phosphorylation of Tau by GSK3 at Two
Different Sites
At the level of degeneration of a single neuron, occurring
in Alzheimer’s disease, it was suggested that ﬁrst takes place
phosphorylation of tau molecule at some speciﬁc sites
and afterwards there is a further phosphorylation and
aggregation of tau protein. Thus, early tau phosphorylation
can be used as an initial marker for neurodegeneration [58].
The phosphorylation of tau, by GSK3, at speciﬁc sites
can be analyzed by the use of antibodies that speciﬁcally
recognize some of those sites. In this way, analysis of phos-
phorylation at serine 202 or at serines 396–404 could be
achieved by using the antibodies AT8 [59] or PHF-1 [60],
respectively. The uses of these antibodies have indicated
that diﬀerent tau molecules could be modiﬁed at those
diﬀerent sites [61]. On the other hand, in mature neurons
tau phosphorylated at the site recognized by PHF-1 is
preferentially present in the axon, whereas tau modiﬁed at
AT8 site is located in the somatodendritic compartment
[61].Temporallobesections,includingtheentorhinalregion
and hippocampus, were studied using the antibody AT8 in
AD patients and controls, to follow the consequences of
that phosphorylation at the level of a single neuron and its
possible relation with tau aggregation. The analysis showed
that tau was modiﬁed at the site recognized by ab AT8 much
earlier than the appearance of aggregated (ﬁbrillar) tau,
suggesting that phosphorylation at the AT8 site represents
an earlier change than tau aggregation [58]. More recently,
by looking at speciﬁc neurons in the brain of Alzheimer’s
disease patients like those present in the CA3 region of the
hippocampus,thesequenceforcellularchangesrelatedtotau
phosphorylation and the posterior formation of aggregates
has been studied with tau antibody AT8. This antibody
recognizes the ﬁrst stages of tau phosphorylation (pretangle
stages) [62], whereas the reaction with tau antibody PHF-
1 could correlate further phosphorylation steps and the
formation of tau aggregates (tangle stages) [63].
Tau phosphorylation (recognized by AT8 antibody) at
regions like CA3 of the hippocampus has been correlated
with regression of synaptic components and memory deﬁcits
[64]. Indeed, although in AD there is neuron death, it has
been suggested that there also could be alive neurons under-
going atrophy [65]. This atrophy could be the consequence
of a metabolic decline [66] (that could be a very early sign
of AD). Indeed, there is a reduced metabolism in those
regions of the brainthat are later aﬀectedinADpatients, and
this glucose hypometabolism may reﬂect a reduced synaptic
activity. This reduced metabolism may induce hypothermia,
decreasing the activity of phosphatases that could result in
the net phosphorylation of GSK3 substrates like tau protein
[66].
Am a i nd i ﬀerence between neuron atrophy and neuron
death is that in the ﬁrst case the neuron remains alive and
could be possible to reactivate it. In fact, we have recently
observed that in patients with AD the accumulation of
phosphotau in a pretangle state does not induce changes in
the dendrites of pyramidal neurons, whereas the presence of
tau aggregates forming intraneuronal neuroﬁbrillary tangles
gives rise to a progressive dendritic atrophy and the loss
of dendritic spines (synaptic disconnection) (Merino-Serrais
P et al. in preparation). Thus, the presence of phosphotau
in a pretangle state in neurons of the human brain does
not necessarily result in severe and irreversible eﬀects. Thus,4 International Journal of Alzheimer’s Disease
it is of great interest to search for possible physiological
conditions in which neurons with a reduced metabolism
and altered synaptic connectivity that may result in the
lack of cognitive functions could be reactivated to regular
functionallyneurons.ThegroupofArendtetal.[67]answers
to that question by showing that topor in hibernating
animals shows a signiﬁcant analogy with the pretangle
stages of AD. Hibernation is a behavioral strategy used
by some mammals to minimize energy expenditure under
inhospitable environmental conditions. During hibernation
overall metabolic rates are greatly reduced and neurons
like those of the CA3 hippocampal regions have a reduced
metabolism [68]. Moreover, tau phosphorylation also takes
place in those neurons, at sites recognized by AT8 antibody,
phosphorylation which is fully reversed in a few hours when
these animals spontaneously interrupt torpor by an arousal
leading the animals to euthermia for 24h approximately
[69]. Furthermore, it has been shown that there is a re-
establishment of mossy ﬁber synapses in CA3 neurons after
arousal [70]. Previous studies have shown that neuronal cell
bodies, dendrites, and spines in hibernating ground squirrels
retract on entry into torpor state. When they return to
euthermia, there is a recovery of the arbor complexity and
spine density [71].
Thus, if topor stage, in hibernation, is similar to the
pretangle stages in AD and it could be reversed, we could ask
if that reversion could also take place in AD. This question
has pros and cons. One of the cons is that the primary
structure of tau from hibernating animals could be diﬀerent
than that of a human being. Thus, tau from hibernating
mammals have been sequenced [70], but no dramatic dif-
ferences with human tau were found. Then, how can we
increase metabolic rate in AD neurons? In a further analysis,
tau protein from Mesocricetus auratus (another hibernating
rodent) has been sequenced and characterized (Leon G et
al. in preparation). The reason of that characterization has
been to perform a ﬁrst step to know if tau protein in
hibernating animals, like M. auratus, could be taken as a
single marker of the process or it may play a role in it.
Thus, tau diﬀerences between this hibernating animal and
nonhibernating organisms like the human being should be
carriedout.Ourresultshaveindicatedthepresenceofseveral
variations at the N-terminal half between M. auratus and
human tau. Some of these variations have been also found in
nonhibernating rodents. However, there are three variations,
in that region, which are only present in the two hibernating
rodents, M. auratus and S. citellus. In addition, there are
another diﬀerences between M. auratus and human tau
like the presence of 10 phosphorylatable residues present
in human but not in M. auratus t a u( L e o nGe ta l .i n
preparation). Many of these phosphorylatable residues could
be possible substrates for ck1, a protein kinase that has been
related with circadian rhythm in nonhibernating organism
[72, 73]. Although additional work should be done, our
observations are compatible with a possible role of tau in
the hibernation process and not being only found as a single
marker.
It could be a possible relationship between hiber-
nation/wake in hibernating mammals and sleep/wake in
humans. Indeed, AD patients exhibit sleep/wake disorders
[74]. However, sleep deprivation has been associated with
GSK3 activation [75], whereas a net GSK3 phosphorylation
takes place in hibernating mammals [76]. Nevertheless,
modulators of sleep/wake cycle, like melatonin, have been
suggested as possible therapeutical compounds for AD [77].
A more related behavior to that of hibernation could
be anesthesia. Anesthesia leads to tau hyperphosphorylation
through inhibition of phosphatase activity by hypothermia
[78], a process that could be similar to that of hibernation.
However, little is known about how is the recovery from
phosphotau to unmodiﬁed tau after anesthesia. In addition,
we do not know if tau phosphorylation is sometimes associ-
ated with the physiological conditions following hibernation
or anesthesia or, like in AD, may play a toxic function [49].
Thus, if phosphotau could be toxic and it is diﬃcult to active
phosphatases for its dephosphorylation, the use of possible
GSK3 inhibitors should be taken into consideration for the
treatment of the disease.
Furthermore, we should look for better analysis to detect
a decreased metabolic rate in damaged CA3 neurons in AD,
and we should look for an answer about how to increase
that metabolic rate in AD neurons. A probable common link
among some of these disorders is the appearance of oxidative
damage that results in neurodegeneration [79, 80].
A possible mechanism has been suggested to explain an
energy depletion in AD. It involves that oxidative stress may
lead to the formation of reactive carbonyl compounds [81]
that appear to increase in AD patients. These compounds
may decrease glucose metabolism yielding to energy deple-
tion in neuronal cells [82]. Also, intracellular Aβ may cause
mitochondrial defects and ATP depletion.
In summary, since neuron atrophy in neurodegenerative
diseases, like AD, has been correlated with tau phosphoryla-
tionbyGSK3,itshouldbetestedinthefutureifbydecreasing
that phosphorylation that atrophy could be reversed or not.
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